Special Issue "Cancers of the Genitourinary System: Pathophysiology, Modeling, and Treatment"

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 9 June 2025 | Viewed by 727

Special Issue Editors

Dr. Hisham Bahmad
E-Mail Website
Guest Editor
The Arkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
Interests: molecular pathology; cancer stem cells; biomarker research
Special Issues, Collections and Topics in MDPI journals
Dr. Wassim Abou-Kheir
E-Mail Website
Guest Editor
Department of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon
Interests: cancer stem cells; solid tumors; biomarkers research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Genitourinary tumors are common neoplasms that include prostate cancer, kidney cancer, bladder cancer, testicular cancer, and cancers of the penis. Each of those cancers is recognized as a heterogeneous disease, and the clinical course is unique to every patient in terms of prognosis and treatment response. With the rapid advancement in the medical field and the wide use of next-generation sequencing techniques to understand cancer, researchers and physicians are moving away from a “one size fits all” strategy in treating the disease to identifying novel biomarkers that can be targeted to specifically treat every patient. Nevertheless, the treatment of most patients with genitourinary cancers requires a multimodality approach that includes surgical intervention, radiation therapy, and chemotherapy.

It is thus crucial to decipher the molecular and cellular mechanisms underlying the initiation and progression of those intractable cancers and accordingly identify the unique biomarkers associated with them to aid in diagnosis and improve prognosis. This approach to the management of genitourinary cancers by applying basic and translational research with bed-side clinical research is the hub for “personalized medicine” in the 21st century and it is an area of great interest to physicians and researchers working in the field, in particular molecular pathologists, and hematology-oncologists. This issue focuses on research and experiences related to cancers of the genitourinary system. This may include deciphering the mechanisms underlying the initiation and progression of genitourinary cancers, including:

pathophysiology; molecular, and cellular mechanism identification of novel cancer biomarker therapeutic targets; improving personalized cancer care using new technologies enhancing cancer diagnoses, management, and outcomes. We invite researchers in molecular pathology, hematology-oncology, genitourinary pathology, stem cells, and other fields of cancer research to submit high-quality reviews related to the issues in this research area.

Dr. Hisham Bahmad
Dr. Wassim Abou-Kheir
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • prostate cancer
  • bladder cancer
  • genitourinary
  • biomarkers
  • therapeutic target
  • personalized medicine
  • targeted therapy
  • genetic aberrations
  • molecular signatures
  • next generation sequencing
  • modeling
  • organoids

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Case Report
Renal Cell Carcinoma Presenting as Syncope due to Saddle Pulmonary Tumor Embolism
Diseases 2022, 10(4), 119; https://doi.org/10.3390/diseases10040119 - 02 Dec 2022
Viewed by 555
Pulmonary embolism (PE) is defined as the obstruction of the pulmonary artery or one of its branches by a blood clot, tumor, air, or fat emboli originating elsewhere in the body. A saddle PE occurs when the obstruction affects the bifurcation of the [...] Read more.
Pulmonary embolism (PE) is defined as the obstruction of the pulmonary artery or one of its branches by a blood clot, tumor, air, or fat emboli originating elsewhere in the body. A saddle PE occurs when the obstruction affects the bifurcation of the main pulmonary artery trunk. We present a case of a 46-year-old man who presented to our hospital due to an episode of syncope. Computed tomography angiography (CTA) of the chest showed extensive PE and abdominal CT scan showed a large 8 cm left renal mass with inferior vena cava (IVC) thrombus. Emergent embolectomy, left total nephrectomy, and IVC tumor removal were performed yielding the diagnosis of clear cell renal cell carcinoma (RCC). Interestingly, our patient did not experience any symptoms related to his RCC until the diagnosis of PE due to syncope, and the asymptomatic tumor was found out to be the possible cause of this PE due to the presence of tumor cells constituting the tumor embolus. It is thus recommended to improve the early screening process for RCC. Besides, clinicians should pay attention to patients presenting with uncharacteristic symptoms of RCC who might present with symptoms of saddle PE. Full article
Show Figures

Figure 1

Back to TopTop